Potent and Orally Efficacious Bisthiazole-Based Histone Deacetylase Inhibitors
ACS Medicinal Chemistry Letters2014Vol. 5(6), pp. 628–633
Citations Over TimeTop 23% of 2014 papers
Abstract
Inspired by the thiazole-thiazoline cap group in natural product largazole, a series of structurally simplified bisthiazole-based histone deacetylase inhibitors were prepared and evaluated. Compound 8f was evaluated in vivo in an experimental autoimmune encephalomyelitis (EAE) model and found to be orally efficacious in ameliorating clinical symptoms of EAE mice.
Related Papers
- → A Focus on the Preclinical Development and Clinical Status of the Histone Deacetylase Inhibitor, Romidepsin (Depsipeptide, Istodax®)(2012)45 cited
- → Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma(2015)31 cited
- → Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance(2019)11 cited
- Clinical development of histone deacetylase inhibitor romidepsin.(2010)
- → Faculty Opinions recommendation of Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.(2016)